Herpes zoster (shingles) immunisation programme 2020 to 2021: evaluation reports, PHE (updated 5th July 2021)

This report evaluates the seventh year of the shingles vaccination programme which offers the shingles vaccine to those turning 70 and 78 years old respectively. Adults remain eligible until their 80th birthday. 5 July 2021 Updated main report. 21 June 2021 Updated report to correct an error in data from one GP IT supplier.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news

Related Links:

J Fam Pract. 2021 Jul;70(6S):S13-S18. doi: 10.12788/jfp.0218.ABSTRACTAt the end of the activity, participants will be able to: • Characterize the burden of herpes zoster infections. • Recommend the recombinant zoster vaccine to patients in accordance with guidance from the Advisory Committee on Immunization Practices. • Implement strategies to increase patient acceptance of herpes zoster and other vaccinations. • Use available resources to increase awareness among patients about the importance and safety of recommended vaccinations.PMID:34432619 | DOI:10.12788/jfp.0218
Source: The Journal of Family Practice - Category: Practice Management Authors: Source Type: research
Date: August 23, 2021 Issue #:  1631Summary:  The FDA has licensed the adjuvanted, recombinant varicella zoster virus (VZV) vaccineShingrix (GSK) for prevention of herpes zoster (shingles) in adults of any age who are or will be at elevated risk because of disease- or therapy-induced immunodeficiency or immunosuppression.Shingrix has been licensed for herpes zoster prevention in adults ≥50 years old since 2017.1 It is the only VZV vaccine currently available in the US;Zostavax, a live-attenuated VZV vaccine, was withdrawn from the market in 2020.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Shingles Shingrix vaccines varicella zoster virus Source Type: research
Philadelphia, London -- 26 July 2021 -- GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
Clin Exp Vaccine Res. 2021 May;10(2):198-201. doi: 10.7774/cevr.2021.10.2.198. Epub 2021 May 31.ABSTRACTCoronavirus disease 2019 (COVID-19) exhibit mild to moderate symptoms, whereas 15% of COVID-19 cases progress to pneumonia, some associated cutaneous findings are also reported as maculopapular eruptions, morbilliform rashes, urticaria, chickenpox-like lesions, and livedo reticularis. The inactivated COVID-19 vaccines are authorized for use in some countries including Turkey. Here, we report an unusual case of varicella-zoster virus (VZV) reactivation in a 68-year-old male patient who was vaccinated against COVID-19. The...
Source: Cell Research - Category: Cytology Authors: Source Type: research
More News: Health | Herpes | Shingles | Shingles (Herpes Zoster) Vaccine | Vaccines | Varicella-Zoster Virus Vaccine